Development · 30 Aug 2026

The Bombay High Court on August 29 questioned the Maharashtra FDA's cancellation of wholesale drug-sale licences linked to Cipla Pharma & Life Sciences' primary distribution facility at Wadki in Pune following inspections that flagged alleged irregularities involving Reactin Plus tablets.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

livemint.com29 Aug 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Cipla

₹1,344.00

▼ -0.15%

Close (EOD), as of 1 Oct 2026 · source

Cipla: results, dividends, orders, the full cited record →

More on Cipla

India's 10 largest pharmaceutical companies have maintained positive average volume growth through every month of 2026 so far, while smaller rivals have seen a more uneven performance.

20 Sep 2026 · 1 publisher

Invagen Pharmaceuticals, a subsidiary of Cipla, has partnered with Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda, for the United States.

7 Sep 2026 · 5 publishers

August saw at least four separate reports related to fake medicines, voluntary recalls, and alleged misbranding, impacting patient safety.

7 Sep 2026 · 1 publisher

Cipla has in-licensed exclusive rights to market Qilu Pharmaceutical's QL2107, a biosimilar alternative of Keytruda, in the US.

4 Sep 2026 · 1 publisher

Cipla has in-licensed a novel bispecific antibody-drug conjugate called rolditamig deuderuxtecan from China's Sino Biopharmaceutical's subsidiary Chia Tai Tianqing Pharmaceutical for exclusive rights to develop and commercialize the drug in India, South Africa and 5 other emerging markets.

2 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.